RxDoctor Payments DataLook up a doctor →

David Bank, MD

Dermatology · Mt Kisco, NYNPI 1558337667

Payments from drug & device makers

$1,204,458in general payments, 2019–2025

Across 513 payments — averaging $2347.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.1M
  • Merz North America, Inc.$132K
  • Galderma Laboratories, L.p.$5K
  • Amgen$722
  • Endo Pharmaceuticals Inc.$400
  • Lilly USA, LLC$311
  • plus $3K from 32 others
$196,036in research payments, 2019–2025

Across 64 payments — averaging $3063.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$190K
  • Merz North America, Inc.$6K

What the payments were for

  • Consulting fees$135,10688%
  • Travel & lodging$9,7296%
  • Food & beverage$9,1316%
  • Education$1070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,204,458 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$182,771
Medicare patients
551
Services billed
7,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$95,491
Fluorouracil67$5,222
Pimecrolimus18$3,060
Halobetasol Propionate63$2,199
Azelaic Acid11$1,666
Desonide14$823
Ketoconazole44$744
Clindamycin Phosphate32$675
Doxycycline Hyclate36$522
Fluocinolone Acetonide11$391
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip24$380
Clobetasol Propionate15$360
Betamethasone Dipropionate11$334
Lidocaine-PrilocaineLidocaine/Prilocaine25$294
Mupirocin40$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$722$95,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Mt Kisco

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →